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Local IL-4Ra Blockade at Sites of Allergic Skin
Inflammation Dampens Inflammation and
Promotes S. aureus Clearance in Mice

Juan-Manuel Leyva-Castillo, PhD1, Alex McGurk1, Raif Geha, MD
FAAAAI1; 1Boston Children’s Hospital.
RATIONALE: Atopic dermatitis (AD) is characterized by Th2-dominated skin inflammation and colonization with S. aureus. Systemic IL-4Ra
blockade is beneficial in AD and results in decreased skin colonization by
S. aureus via mechanisms that are not well understood.
METHODS: The skin of Balb/c mice was sensitized epicutaneously with
ovalbumin (OVA) for 8 days and then injected intradermally with a single
dose of anti-IL-4Ra blocking antibody or isotype control followed by
topical application of S. aureus or saline. Two days later the sensitized skin
was examined for cell infiltrates by flow cytometry, cytokine mRNA
expression by quantitative PCR, global gene expression by transcriptome
analysis, and bacterial burden by in vivo imaging and counting colonyforming units in skin homogenates.
RESULTS: IL-4Ra blockade in OVA sensitized skin significantly
decreased epidermal thickening, diminished eosinophil and mast cell
infiltration by ;30% (p<0.05) and increased cutaneous Il17a mRNA
levels (1.5 folds, p<0.05) compared to control, without affecting cutaneous
Il4 and Il13 mRNA expression or the systemic response to OVA.
Transcriptome analysis revealed that IL-4Ra blockade increased the
expression of genes regulated by IL-1b and IL-17A. IL-4Ra blockade in
OVA sensitized and S. aureus infected skin had a similar effect and
Importantly, it decreased S. aureus load (2063.8x103 versus 361.6x103
CFUs, p<0.005).
CONCLUSIONS: Local IL-4Ra blockade in an antigen-driven mouse
model of AD improves allergic skin inflammation and enhances S. aureus
clearance, possibly by enhancing the local responses known to restrain
cutaneous S. aureus infection.
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Mast Cells are Locally Activated and Respond to
MRGPRX2 Stimulation in Atopic Dermatitis Ex
Vivo Skin Biopsies

Melina Butuci, PhD1, Zachary Benet1, Alan Wong1, Julia Schanin1, Alan
Xu1, Amol Kamboj, MD1, Brad Youngblood, PhD1; 1Allakos, Inc.
RATIONALE: Atopic dermatitis (AD) is characterized largely by type 2
inflammation of the skin and often debilitating symptoms such as pruritis.
Mast cells (MCs) and eosinophils are considered drivers of itch in skin
diseases via crosstalk with sensory neurons. The identification of
MRGPRX2 as a MC-specific receptor for a broad range of neuropeptides
further implicates crosstalk between MCs and nerves in neurogenic
inflammation. While MCs and eosinophils have been shown to be elevated
in AD, their roles in pathogenesis remain poorly understood. We hypothesized that MRGPRX2-mediated MC activation contributes to local
inflammation and sensory neuron excitation in AD.
METHODS: Single-cell suspensions were prepared by enzymatic
digestion of fresh biopsies from AD patients and non-diseased skin tissue.
Fresh biopsies were cultured ex vivo overnight followed by collection of
supernatants to quantify mediators. Flow cytometry was used to assess
MRGPRX2 activity.
RESULTS: MCs in AD biopsies displayed increased expression of
activation and degranulation markers. In addition, supernatants from ex
vivo cultured AD biopsies had elevated levels of MC- and eosinophilderived mediators and cytokines, indicative of local functional activation
and inflammation. Biopsy supernatants also showed elevated levels of
endogenous MRGPRX2 ligands and ex vivo stimulation of AD skin
biopsies with MRGPRX2 ligands induced significant MC activation.
Lastly, MRGPRX2-mediated MC activation significantly activated human
sensory neurons.
CONCLUSIONS: MCs are locally activated and respond to MRGPRX2
ligands, implicating MCs as potential pathogenic drivers of chronic skin
inflammation and itch. Targeting both MRGPRX2-mediated MC

activation and eosinophils may represent a potential therapeutic strategy
for AD patients.
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Epigenetic and Transcriptional Dysregulation in
T cells of Patients with Atopic Dermatitis

Amy Eapen, MD, MS1, Leah Kottyan, PhD2, Sreeja Parameswaran3,
Carmy Forney4, Lee Edsall, PhD4, Daniel Miller5, Omer Donmez4,
Matthew Weirauch, PhD3, Katelyn Dunn4, Xiaoming Lu5, Marissa Granitto4, Hope Rowden4, Adam Magier, MS3, Mario Pujato4, Xiaoting Chen4,
David Bernstein, MD FAAAAI6, Ashley Devonshire, MD MPH7, Marc
Rothenberg, MD PhD FAAAAI3; 1Henry Ford Health System, 2Cincinnati
Children’s Hospital Medical C, 3Cincinnati Children, 4Cincinnati Children’s Hospital Medical Center, 5CCHMC, 6Bernstein Allergy Group,
Inc, 7University of Cincinnati, Cincinnati Chi.
RATIONALE: Atopic dermatitis (AD) is linked to genetic and environmental risk factors. The effect of these factors on molecular and
transcriptional events is not well understood. Immunologically, AD
involves skin barrier defects and CD4+ T cells that produce inflammatory
cytokines and amplify epidermal dysfunction Our objective was to
investigate epigenetic mechanisms that may account for genetic susceptibility in CD4+ T cells.
METHODS: We measured chromatin accessibility (ATAC-seq), NFKB1
binding (ChIP-seq), and gene expression (RNA-seq) in anti-CD3/CD28
stimulated CD4+ T cells from 6 subjects with active moderate-to-severe
AD and 6 age-matched non-allergic controls.
RESULTS: AD genetic risk loci were enriched for open chromatin regions
in stimulated CD4+ T cells. The majority of ATAC-seq peaks were shared
between matched AD-control pairs, consistent with those sections of
chromatin being equally available. In contrast, NFKB DNA binding motifs
were enriched in AD-dependent open chromatin. NFKB1 ChIP-seq
identified genomic regions that were more strongly bound in AD cases,
more strongly bound in controls, or shared between cases and controls.
Chromatin that was strongly accessible and bound by NFKB1 in AD was
enriched for AD genetic risk variants. Using whole genome sequencing
data, we identified genotype-dependent accessible chromatin at AD risk
loci corresponding to 32 genes with genotype-dependent expression in
stimulated CD4+ T cells.
CONCLUSIONS: The response of CD4+ T cells to stimulation is ADspecific and results in differential chromatin accessibility and transcription
factor binding. These differences in transcriptional regulation result in
epigenetic and transcriptional dysregulation in CD4+ T cells of patients
with AD.
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